President Trump is expected to announce a new drug pricing initiative in the Oval Office this Friday, accompanied by a group of state governors. According to an administration official, the policy will implement 'most favored nation' (MFN) pricing for specific drugs covered under Medicaid across all 50 states.

The 'most favored nation' model is designed to link the price of drugs in the United States to the lower prices paid by other countries. By adopting this approach, the administration intends to lower costs for the Medicaid program, which serves as a primary healthcare provider for millions of low-income Americans. The announcement comes as drug affordability remains a significant issue for voters ahead of the election cycle.

While the administration frames this as a necessary step to curb rising costs, the policy has historically faced scrutiny from pharmaceutical industry groups and some policy analysts. Critics often argue that such price controls could stifle innovation or limit access to newer medications. However, the current reporting focuses primarily on the administration's stated goal of providing financial relief to state budgets and individual patients. The specific list of drugs subject to this pricing model and the exact mechanism for implementation are expected to be detailed during the formal announcement.